Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track XNCR with free AI briefings, catalyst countdowns, and dilution alerts.

XNCR · Xencor Inc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$555.7M Cash on Hand
62.9mo Cash Runway
Follow XNCR by email Get an email when XNCR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about XNCR, unsubscribe in one click. Privacy

📣 What XNCR Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
XmAb942 Ulcerative Colitis (UC) Phase 1/2 · NCT06619990 Recruiting
Izuralimab (XmAb23104) Sarcoma Phase 2 · NCT05879185 Terminated
Vudalimab (XmAb20717) Biliary Tract Cancer Phase 2 · NCT05297903 Completed
Plamotamab (XmAb13676) Diffuse Large-cell B-cell Lymphoma Phase 2 · NCT05328102 Terminated
Tidutamab (XmAb18087) Merkel Cell Carcinoma Phase 1/2 · NCT04590781 Terminated
Obexelimab (XmAb5871) Systemic Lupus Erythematosus Phase 2 · NCT02725515 Completed
XmAb27564 Psoriasis Phase 1 · NCT06005792 Terminated
XmAb412 Monoclonal Bispecific Antibody Not Applicable - Healthy Adult Participants Phase 1 · NCT07713485 Recruiting
Anti-CLDN6/CD3 Bispecific Antibody XmAb541 Ovarian Cancer Phase 1 · NCT07593092 Recruiting
XmAb657 Healthy Phase 1 · NCT07284797 Recruiting
IL-12-Fc Fusion Protein XmAb662 Solid Tumors Phase 1 · NCT05996445 Terminated
XmAb7195 Healthy Volunteers Phase 1 · NCT02881853 Completed
Anti-B7-H3/CD28 Bispecific Antibody XmAb808 Ovarian Cancer Phase 1 · NCT07593092 Recruiting
Anti-ENPP3/Anti-CD3 Bispecific Antibody XmAb819 Clear Cell Renal Cell Carcinoma Phase 1 · NCT05433142 Recruiting
Anti-CD30 Monoclonal Antibody XmAb2513 Hodgkin Lymphoma Phase 1 · NCT00606645 Completed
Pavunalimab (XmAb22841) Metastatic Melanoma Phase 1 · NCT05695898 Terminated

Also used in these trials (approved or third-party drugs, not XNCR's own candidates): Lenalidomide, Regorafenib, Tafasitamab (XmAb5574), Ipilimumab, Abiraterone Acetate, Pembrolizumab, Enzalutamide, Docetaxel Anhydrous.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

XNCR holds $555.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $26.5M/quarter from operations, an estimated runway of 62.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 10 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when XNCR files for a raise →

👥 Who Owns XNCR

Insiders 1.6% Institutions (314 holders) 98.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 10,816,417 14.41% 2026-09-30
PRIMECAP MANAGEMENT CO/CA/ Institution (13G, 5%+) 9,879,855 13.17% 2026-09-30
BVF PARTNERS L P/IL Institution (13G, 5%+) 7,133,720 9.51% 2025-12-31
RA Capital Management, L.P. Institution (13G, 5%+) 4,736,739 6.31% 2026-03-23
STATE STREET CORPORATION Institution (13G, 5%+) 4,507,254 6.01% 2025-12-31
The Toronto-Dominion Bank Institution (13G, 5%+) 3,871,296 5.16% 2026-09-30
Bassil I Dahiyat
PRESIDENT & CEO, Director · +583,748 options
Insider 546,316 0.73% 2026-03-05
John R Desjarlais
SR. VICE PRESIDENT & CSO · +149,440 options
Insider 263,831 0.35% 2026-03-05
Celia Eckert
SVP, GENERAL COUNSEL · +112,080 options
Insider 76,918 0.10% 2026-03-05
Bart Jan Cornelissen
SR. VICE PRESIDENT & CFO · +116,750 options
Insider 65,798 0.09% 2026-11-11
Nancy Valente
EVP, Chief Development Officer
Insider 49,169 0.07% 2025-05-02
Barbara Klencke
Director · +47,976 options
Insider 29,974 0.04% 2026-06-16

Share count 75,039,689 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full XNCR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for XNCR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.